NCT03108131 2025-05-28
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
6 trialsNCT04214418 2024-12-18
MEKiAUTO
Columbia University
Phase 1/2 Terminated
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03566485 2021-08-11
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated
NCT01813214 2019-02-26
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
Phase 2 Terminated
NCT01495988 2017-10-24
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
Phase 2 Terminated